Aspire Biopharma Holdings, Inc. (ASBP) Form 10-Q — May 15, 2026
Aspire Biopharma Holdings (ASBP) reported a net loss of $3.2 million for Q1 2026, with negligible revenue of $28,353 from nutraceutical sales. The company executed two reverse stock splits (1:40 in January and 1:30 in May 2026) to maintain Nasdaq listing compliance, a move that typically signals severe financial distress and dilution risk for existing shareholders. Despite the bearish technicals, the company raised $21 million in gross proceeds through the issuance of Series A Convertible Preferred Stock in two tranches during Q1 and early Q2 2026.
Key figures
- Revenue
- 28353
- Total Debt
- 3152432
- Cash Position
- 5857024
- Shares Outstanding
- 167470
- Reverse split ratio 1
- 1:40
- Reverse split ratio 2
- 1:30
- Preferred stock raised q1
- 11000000
- Credit facility commitment
- 22500000
- Proposed acquisition value
- 30000000
- Preferred stock raised subsequent
- 10000000
Price after filing
Close on the filing date to close N calendar days later (from $5.61). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.